Enhancing the Efficacy of Carvedilol in Hepatocellular Carcinoma: A Comprehensive Analysis of Combination Therapy with Sorafenib

• Combination of carvedilol and sorafenib synergistically inhibits HCC cell proliferation and induces apoptosis. • In vivo, the combination significantly reduces tumor growth compared to either drug alone. • The synergistic effect is mediated via suppression of the PI3K/Akt/mTOR signaling pathway. • This combination therapy may offer a new treatment option for advanced HCC patients.